8-K: Catalyst Pharmaceuticals Reports Record Q1 2025 Revenue, Reaffirms Full-Year Guidance

Catalyst Pharmaceuticals announces record first quarter 2025 financial results with $141.4 million in total revenue and reaffirms its full-year revenue guidance of $545 million to $565 million.

Summary

• Catalyst Pharmaceuticals reported record first quarter 2025 financial results.
• Total revenue for Q1 2025 reached $141.4 million, a 43.6% increase year-over-year.
• FIRDAPSE revenue was $83.7 million, up 25.3% year-over-year.
• AGAMREE revenue was $22.0 million, compared to $1.2 million in the prior year period.
• FYCOMPA revenue was $35.6 million, a 17.1% increase year-over-year.
• GAAP net income was $56.7 million, or $0.47 per basic share.
• Non-GAAP net income was $86.6 million, or $0.71 per basic share.
• The company reaffirmed its full-year 2025 revenue guidance of $545 million to $565 million.
• Cash and cash equivalents totaled $580.7 million as of March 31, 2025.
• Health Canada accepted the New Drug Submission for AGAMREE with Priority Review.
• FIRDAPSE was launched in Japan by sub-licensee DyDo Pharma.
• A settlement agreement was reached with Teva Pharmaceuticals regarding a generic version of FIRDAPSE, preventing Teva from marketing its generic product before February 25, 2035, subject to certain conditions.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with record revenues, strong growth across key products, reaffirmed guidance, and a solid cash position. The settlement agreement with Teva and potential approval of AGAMREE in Canada further contribute to the positive sentiment.

Positives

• Record first quarter revenue demonstrates strong commercial execution.
• Significant year-over-year revenue growth for FIRDAPSE, AGAMREE, and FYCOMPA indicates strong demand.
• Reaffirmation of full-year revenue guidance provides confidence in future performance.
• Strong cash position and no debt provide financial flexibility.
• Health Canada's acceptance of the AGAMREE submission with Priority Review is a positive regulatory development.
• The settlement agreement with Teva provides patent protection for FIRDAPSE until 2035.
• The launch of FIRDAPSE in Japan expands the product's global reach.

Negatives

• FYCOMPA revenue is expected to be impacted by the loss of market exclusivity for tablets in May 2025 and oral suspension in December 2025.
• Two remaining ANDA litigations regarding Catalysts FIRDAPSE patents continue.

Risks

• The company's future results could differ materially from forecasted results due to various factors.
• The impact of the pending Paragraph IV litigation relating to FIRDAPSE could adversely affect Catalyst if the results of these litigation matters are adverse.
• The company's revenue forecasts for 2025 may not be accurate.
• The company may not be able to complete any acquisitions of additional products, or the timing of any such acquisitions may be delayed.

Future Outlook

The company reaffirms its full-year 2025 revenue guidance, expecting total revenues between $545 million and $565 million, FIRDAPSE revenue between $355 million and $360 million, AGAMREE revenue between $100 million and $110 million, and FYCOMPA revenue between $90 million and $95 million.

Management Comments

• Catalysts exceptional first quarter performance underscores the continued strength of our commercial strategy and the growing demand for our differentiated therapies, said Richard J. Daly, President and CEO of Catalyst.
• Our 43.6% year-over-year total revenue growth for the first quarter of 2025 is a testament to our focused execution and the increasing recognition of the value that our therapies deliver.
• Looking ahead, we see meaningful opportunities to further establish AGAMREE as a cornerstone therapy in the Duchenne muscular dystrophy (DMD) market and expand FIRDAPSEs clinical utility in Lambert-Eaton myasthenic syndrome (LEMS), addressing a significant unmet need for patients in both markets.
• We continue to evaluate strategically aligned opportunities to strengthen our portfolio and expand our reach to serve more patients.
• Building on our momentum, we are confident in our ability to execute our 2025 strategic priorities and drive long-term growth.

Industry Context

Catalyst's focus on rare diseases and strategic in-licensing aligns with industry trends of companies targeting niche markets with high unmet needs. The growth in AGAMREE revenue reflects the increasing attention and investment in DMD therapies. The settlement with Teva is crucial for maintaining market exclusivity for FIRDAPSE, a common strategy in the pharmaceutical industry to protect revenue streams.

Comparison to Industry Standards

• Comparing Catalyst's revenue growth to other rare disease companies like Sarepta Therapeutics or BioMarin Pharmaceutical, the 43.6% year-over-year increase is competitive.
• The cash position of $580.7 million provides a strong foundation for future acquisitions and R&D investments, similar to companies like Horizon Therapeutics before its acquisition.
• The FIRDAPSE settlement with Teva mirrors similar patent protection strategies employed by companies like AbbVie with Humira to delay generic entry.
• AGAMREE's potential approval in Canada would position it as the first authorized treatment option for DMD, giving it a competitive advantage over existing off-label treatments, similar to how Vertex Pharmaceuticals' Kalydeco revolutionized the cystic fibrosis market.

Legal Proceedings

• Two remaining ANDA litigations regarding Catalysts FIRDAPSE patents continue.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and positive outlook.
• Patients will benefit from the continued availability and potential expansion of treatment options.
• Employees will benefit from the company's growth and stability.
• The company's financial strength allows it to continue investing in research and development, benefiting the rare disease community.

Next Steps

• Continue advancing the SUMMIT Study to gather long-term real-world evidence of AGAMREE's benefits.
• Monitor the progress of the AGAMREE New Drug Submission in Canada.
• Manage the anticipated loss of market exclusivity for FYCOMPA.
• Continue to evaluate strategically aligned opportunities to strengthen the portfolio and expand reach.
• Prepare for the conference call and webcast on May 8, 2025.

Key Dates

Keywords

Catalyst Pharmaceuticals, FIRDAPSE, AGAMREE, FYCOMPA, Revenue, Financial Results, Q1 2025, Guidance, Rare Diseases, LEMS, DMD